Enrichment, Development, and Assessment of Indian Basil Oil Based Antiseptic Cream Formulation Utilizing Hydrophilic-Lipophilic Balance Approach

Table 5

Antimicrobial activity of basil oil, developed cream formulations, and marketed herbal antiseptic cream.

Microorganisms	Net zone of inhibition^a (mm)
	Basil oil^b	CR4^c	BCR4^c	CR6^c	BCR6^c	Marketed antiseptic cream^c
Antibacterial activity
Staphylococcus aureus (MTCC 96)	7.3±1.15	5.6±0.57	0	7.6±1.52	1.6±0.57	10.6±1.15
Staphylococcus epidermidis (MTCC 435)	13.6±1.52	11.0±1.00	2.3±0.57	10.3±2.0	3.0±1.00	10.0±2.00
Streptococcus mutans (MTCC 890)	5.6±1.52	5.6±0.57	0	9.0±1.00	1.6±0.57	7.3±0.57
Salmonella typhi (MTCC 733)	6.6±1.15	5.0±1.00	0	7.0±1.00	1.3±0.57	8.6±1.15
Yersinia enterocolitica (MTCC 861)	10.0±2.0	6.0±1.00	0	11.3±1.52	1.3±0.57	8.0±2.00
Klebsiella pneumoniae (MTCC 109)	4.6±1.15	1.66±0.57	0	7.0±1.00	1.6±0.57	8.6±1.52
Enterobacter aerogenes (MTCC 111)	5.0±1.00	1.66±0.57	0	9.0±1.00	1.0±0.00	5.0±1.00
Antifungal activity
Candida albicans (MTCC 1637)	8.6±1.15	4.3±0.57	0	7.0±1.00	1.6±0.57	9.6±1.52
Aspergillus niger (MTCC 281)	10.0±2.00	7.3±0.57	0	7.6±1.15	1.0±0.00	7.0±1.00
Microsporum gypseum (MTCC 2830)	8.3±1.52	7.0±1.00	0	6.0±1.00	1.0±0.00	6.3±1.15

aMean ± SD, 𝑛=3.
^bAgar disc diffusion method.
^cAgar well diffusion method.
BCR4 and BCR6; Placebo of CR4 and CR6, respectively.